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Abstract
Background: Characterization of fatal and nonfatal reactions to food indicates that the majority of
reactions are due to the ingestion of prepared foods rather than the nonprocessed allergen. In an
ongoing study that used a double-blind placebo-controlled food challenge to investigate peanut allergy and clinical symptoms, the observed reaction severity in four of the first six subjects was greater
than anticipated. We hypothesized that this was due to differences in the composition of the challenge vehicle. Objective: The aim was to investigate whether the severity of observed challenge reactions would be repeated on rechallenge with a lower fat challenge vehicle. Methods: Peanut-allergic
subjects were rechallenged with a lower fat recipe after reacting more severely than was anticipated
to an initial peanut challenge. Similar challenge vehicle recipes were used, the only difference being
the lower fat content (22.9% compared with 31.5%). The peanut content of the two recipes was analyzed using RAST inhibition studies and ELISA tests. Results: Three of four subjects reacted to much
smaller doses of peanut protein on rechallenge (mean dose equivalence –23 times less peanut) with
the lower fat recipe. RAST inhibition showed that neither recipe altered epitope recognition. The
higher fat recipe required twice as much peanut to cause 50% inhibition. ELISA detected far lower
levels of peanut in the higher fat recipe (220 000 parts per million [ppm]) than in the lower fat recipe
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(990 000 ppm). Conclusion: The fat content of a challenge vehicle has a profound effect on the reaction
experienced after allergen ingestion. This is another factor to be considered in assessing the risk of
certain foods to food-allergic consumers and adds another dimension to clinical, research, and regulatory practice.
Keywords: anaphylaxis, food allergy, food challenge, food matrix, IgE, peanut

Introduction
The incidence of anaphylaxis as a result of food allergen ingestion is increasing [1]. Peanuts
and tree nuts cause most food-related anaphylactic reactions [2, 3]. Retrospective analysis
and characterization of fatal allergic reactions have shown that the majority of reactions
were due to the ingestion of peanut as an ingredient in a prepared food or dish rather than
to unadulterated peanuts [2, 4].
The risk of suffering an allergic reaction of any description is dependent on many factors, some of which may be responsible for the variation of low-dose reactivity (threshold
dose) observed in food-allergic individuals [5]. Different forms of cooking appear to affect
in vitro assessments of the allergenicity of peanut [6]. Another factor may be the presentation of the allergen in different food preparations or matrices.
Peanuts are eaten in many different forms: as peanut butter, as roasted kernels, or as
ingredients in other foods either as flour, a paste, or as peanut pieces of varying size. Although
most first reactions to peanut are seen in the home, subsequent reactions increasingly occur
outside the home [7], with Asian-style food restaurants, ice-cream shops, and bakeries
commonly cited as being where serious reactions most often occur [8]. Desserts and confectionery are also often highlighted as common causes of accidental allergen exposure [7].
Double-blind placebo-controlled food challenge (DBPCFC) is the gold standard for diagnosing food allergy [9]. A challenge consists of an allergenic test food and a vehicle,
which is an inert food or food mix in which the test food is delivered. Various strategies
are employed to ensure blinding [9–11]. Our experience with peanut DBPCFC led us to try
and improve the blinding of our own and other groups’ recipes to optimize peanut masking.
Fat is known to affect both the physical properties and the flavor of a food [12]; consequently,
the fat content of a well-established chocolate recipe to mask peanut was increased from
22.9% fat to 31.5%.
In the course of an ongoing study into threshold doses of peanut in allergic subjects, we
observed unexpectedly severe reactions to peanut in challenges using a recipe that had
been modified by having its fat content increased. Here, we report the less severe reactions
induced by repeat challenge with the lower-fat peanut recipe.
Materials and methods
Ethical approval for a study looking at the relationship between peanut allergens and clinical symptoms was obtained from the Southampton and SW Hampshire Local Research
Ethics Committee. All subjects gave written informed consent. All DBPCFC took place in
the Wellcome Trust Clinical Research Facility, which is fully equipped for physiological
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monitoring and resuscitation. All subjects were well on the day of the challenge, and intravenous access was established prior to the challenge commencing.
The challenge protocol consisted of 11 active doses of increasing magnitude randomly
interspersed with four placebo doses. The adequacy of blinding had been determined by
tasting sessions that mimicked the challenge procedure using volunteers who were not
food-allergic. Each active dose delivered 1, 2, 5, 10, 20, 50, 100, 250, 500 mg, and 1, 2, 4 g of
peanut protein, respectively. Doses were given between 15 and 30 min apart depending
on clinical history [9].
The first six challenges administered the 31.5% fat recipe, but the study was suspended
because four of the subjects progressed further through the challenge and reacted more
severely than had been anticipated from their clinical history and from their previous lowdose challenges [13]. Ethical approval was obtained to rechallenge these subjects with the
22.9% fat recipe. All rechallenges took place between 3 and 6 months after the initial challenge.
Both peanut recipes were made using the same method: cooking chocolate (32.9% fat),
vanilla essence, mint essence, icing sugar, salt, commercial vegetable fat (Trex), and commercial roasted and partially defatted peanut flour (12% fat, 50% protein; Golden Peanut
Company, Alphretta, Georgia, USA) were melted and mixed together for 30 min to form a
homogeneous mix of ingredients. No cooking was involved. The mixture was allowed to
set and then kept refrigerated until use (maximum storage 4 weeks). The only difference
between the two recipes was the amount of fat used in the final formulation (22.9% fat
compared with 31.5% fat), which led to a very small difference in the percentage peanut
protein of the recipes (7.96% compared with 7.25%).
In vitro evaluation of the peanut challenge recipes was carried out to determine whether
levels of detectable peanut differed between the two recipes. The first was a commercial
sandwich ELISA (Veratox for peanut, Neogen Corporation, Lansing, Michigan, USA),
which utilizes polyclonal rabbit antibodies specific for peanut and has a detection limit of
2.5 parts per million (ppm). Premarketing assessment of this commercial assay included
validation in a large variety of chocolate matrices with differing amounts of fat in them
(personal communication, Neogen Corporation). ELISA tests were performed according
to the manufacturer’s instructions.
The second system was RAST inhibition, which utilizes the serum of peanut-allergic
subjects. RAST inhibition was generally performed by the method described in Adolphson
et al. [14], where the solid phase was prepared by attaching roasted peanut protein to cyanogen bromide-activated microcrystalline cellulose. A standard curve was generated using an extract of partially defatted peanut flour and mixing various dilutions with the solid
phase. Various dilutions of the peanut-in-chocolate challenge material extracts were also
mixed with solid phase support. Pooled sera from six individuals with documented peanut
allergy were added to each set of tubes. Tubes were incubated with serum overnight and
washed three times with buffer. Radioactive iodine-125-labeled antihuman IgE was added
and incubated overnight, washed three times with buffer, and the amount of IgE bound to
the solid phase was determined by counting in a solid scintillation counter [15].
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Results
In contrast to the challenge results seen with the 31.5% fat, no challenge subject reacted at
a higher dose than was anticipated and all reactions were mild/moderate with the 22.9%
fat recipe. Table 1 shows the reaction details of the four peanut challenges and rechallenges,
and details of their most severe community reaction.
When comparing the challenge results of subjects 1, 2 and 4, it can be seen that they ate
far more peanut protein in the first challenge before experiencing any symptoms than they
did in the second challenge. Also, the symptoms experienced were more severe in the first
challenge compared with the second. Subject 3 consumed the same dose of peanut in both
challenges.
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Table 1. Reactions during first and second peanut challenges

Length of
first
challenge
(min)

First
challenge
treatment

Length of
second
challenge
(min)

Second
challenge
treatment

Dose
equivalence
(31.5% fat
chocolate vs.
22.9% fat
chocolate)

Study
number

Age
(years)

1

32

14

Peri-oral
angiooedema,
urticaria

Generalized
angiooedema,
rhinitis

936

263

i.m. epi, i.v.
antihistamine, i.v.
steroid

Peri-oral
angiooedema
and
pruritus

86

125

i.v. antihistamine,
i.v. steroid

26 times

2

20

12

Peri-oral
angiooedema,
urticaria,
vomiting

Generalized
urticaria,
vomiting

186

170

Oral antihistamine, i.v.
steroid,
i.m. epi

Peri-oral
angiooedema
and pruritus,
vomiting

16

60

Oral antihistamine, i.v.
antihistamine,
oxygen

12 times

3

28

17

Abdominal
pain,
vomiting

Abdominal
pain,
nausea

36

150

Oral antihistamine

Abdominal
pain,
nausea

36

100

i.v. antihistamine,
i.v. steroid

0

4

25

7

Peri-oral
pruritus
and
urticaria

Nausea,
 peak
flow

186

175

i.v. antihistamine

Peri-oral
angiooedema
and pruritus,
nausea

6

35

Oral antihistamine, i.v.
antihistamine, i.v.
steroid

31 times

5

Second
challenge
symptoms

Second
challenge
cumulative
dose
(mg peanut
protein)

SPT
weal
(mm)

Symptoms
on history

First
challenge
symptoms

First
challenge
cumulative
dose
(mg peanut
protein)
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RAST inhibition showed that the amount of peanut-specific IgE bound to the solid
phase is inversely proportional to the amount of peanut IgE-binding sites in the extracts
(Fig. 1). Similarity in the slopes of the curves generated to the slope of the standard suggests that these products contain similar allergenic epitopes [16]. It can be seen that twice
as much of the higher-fat recipe was needed to cause 50% inhibition of binding, compared
with the lower-fat recipe; in other words, half the allergen is available in the high-fat recipe.
This indicates that in vitro, the amount of fat present has a negative effect on the inhibitory
action of the extract. The mode of action may be on biological activity or may be purely
due to the physical properties of the fat. Whatever the mechanism, these in vitro observations agree with the in vivo observations.

Figure 1. Comparison of peanut in chocolate challenges: 31.5% and 22.9% fat.

The ELISA results showed that there were 990 000 ppm of peanut detected in the 22.9%
fat recipe but only 220 000 ppm in the 31.5% fat recipe. This result cannot be due to the
nonspecific binding of fat to the plate surface, as the plate comes precoated with an antipeanut antibody.
Discussion
As well as having physiological effects on the body such as delaying stomach emptying
and increasing the release of cholecystokinin (CCK) [17], the presence of fat in food is
known to influence taste perception [18]. Advances have been made into improving the
acceptability of low-fat foods, but producing low-fat foods with flavors similar to their
high-fat equivalent has been hard to achieve [19]. The fat content of a food has been shown
to both delay the onset of taste perception and to reduce its intensity, particularly when
the flavor molecule is lipophilic [20]. This is thought to be because lipophilic flavors are
released more slowly from oils than from water [18]. As peanuts are such a high-fat food
(46% fat), it was assumed that the unidentified flavor molecule was lipophilic; therefore,
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in an effort to improve blinding, the fat content of the challenge vehicle was increased from
the established recipe.
We have shown that peanut-allergic subjects consumed larger doses of allergen when
the fat content of the vehicle was higher. They did not experience their oral “early warning
sign” that a reaction was developing, which is generally seen in all peanut-allergic patients
[21]. The lack of these early/oral symptoms is thought to be because allergens contained in
a high-fat food matrix are released, and thereby absorbed, more slowly than if they were
in a lower-fat matrix. Our finding suggests that food-allergic people eating high-fat foods
that contain an allergen do not get the same warning symptoms as they would if the allergen was in a low-fat food or eaten in its unadulterated native form. Elimination or lack of
these premonitory oral sensations results in more of the food being eaten before a reaction
starts. This suggestion is substantiated by observations made during DBPCFC using capsules to disguise the food. Symptoms experienced by subjects differed from community
reactions, as the allergen did not come into contact with the oral mucosa [22]. We suggest
that subject 3 in our study consumed the same dose of peanut in both challenges because
she had never experienced oral symptoms; masking the allergen from mast cells found in
her oral mucosa did not affect her disease manifestation during challenge.
As all rechallenges occurred between 3 and 6 months after the initial challenge, we did
not anticipate that any immunomodulatory effects from the first challenge would still be
acting, so the reduced severity of the reactions is unlikely to be due to a hangover effect
from the first challenge.
Both in vitro tests show that the presence of fat significantly inhibits allergen detection
(although the effect was less marked on RAST inhibition than on ELISA). We propose that
the lack of early/oral symptoms is because allergenic epitopes are concealed by the relatively high-fat food matrix and are detected only after digestion of the fat that occurs in the
stomach and small intestine. Once the allergen is released from its fatty matrix and is encountered by epithelial cells, it is available to circulating allergen-specific IgE. However,
as larger doses of allergen will have been eaten when this occurs, the allergic reaction will
be more severe. Reactions to allergen can vary according to circumstances. Hospital-based
challenges are designed to minimize confounding factors. There are few reports of repeat
challenge with peanut [23]. Our data suggest that the food matrix has a critical impact on
allergen availability, and we infer that it may critically affect the reactions to allergen exposure in the community.
Our study has some limitations. Firstly, the peanut concentration of each recipe was
not exactly equal due to volume factors. However, the difference in peanut content was
only 0.71% and would not result in the large difference seen in the detectable peanut between the two recipes, which can be explained only by a concealing effect of fat in the
challenge vehicles. The results of the in vitro tests support the hypothesis that the allergen
is less available in the higher-fat recipe compared with the original recipe, despite near
equivalence of peanut protein. The ELISA results indicate that it is harder to extract peanut
proteins from the higher-fat recipe, and this has implications in using ELISA test kits for
detecting peanut in different types of foods.
Secondly, it has been reported that certain methods of food processing can enhance,
reduce, or eliminate the allergenic potential of a food [6, 24], but these studies have focused
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on the effect of processing on specific IgE binding in vitro and not on the bioavailability of
the allergen. Our findings are very important for food allergy sufferers, who appear to
experience more reactions to foods prepared by others, in restaurants, etc. It could explain
the strong tendency for fatal reactions to occur to hidden rather than native allergens.
Thirdly, the numbers involved are small, and a more complete observation could be
made if additional challenges were carried out. However, it would be unethical to ask peanutallergic patients to undergo two challenges, one of which would be likely to cause a severe
reaction. We obtained ethical approval to rechallenge four subjects, as they had already
had a serious reaction and rechallenge would clinically clarify the unexpected nature of
their previous challenge result.
Finally, reactivity may vary with time, but this variability can usually be accounted for
by other circumstances such as location and dose [25]. By repeating the challenges in the
same location, to the same protocol, with everything identical apart from the fat content of
the vehicle, this variability in reactivity can be considered to be minimal by comparison.
Conclusion
From our observations from DBPCFC, we have been able to show that the fat content of
challenge recipes has a profound effect on the reaction of the challenge subject. In vitro
tests also show that fat has an effect on allergen bioavailability. This finding is significant
for all people with food allergy, physicians involved in the treatment of food-allergic patients, food and catering industries, and all people working in restaurants and other eating
establishments.
The knowledge that it is not just the presence of an allergen in a food that is important
but how it behaves in a food matrix adds another dimension to clinical and research practice and to the approaches taken by the food and catering industry to the issue of food
safety for food-allergic consumers.
Finally, when complex food matrices are being further investigated, the in vitro test
used must be considered carefully, as the measured allergen content of the food preparation may differ considerably between tests because of the effects of food matrices on the
efficiency of allergy extraction.
Acknowledgments – We thank the Food Standards Agency, which funded the research into peanut
allergy during the time these observations were made; all staff of the Wellcome Trust Clinical Research Facility at Southampton General Hospital; the four peanut-allergic subjects for their willingness to be rechallenged; and Professor Hugh Sampson for sharing his challenge recipe.
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